World Journal of Surgery

, Volume 42, Issue 4, pp 1036–1045 | Cite as

Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma

  • Wickii T. VigneswaranEmail author
  • Diana Y. Kircheva
  • Adrian E. Rodrigues
  • Sydeaka Watson
  • Amy Durkin Celauro
  • Berkley Rose
  • Hedy L. Kindler
  • Aliya N. Husain
Original Scientific Report



Complete macroscopic resection surgery, pleurectomy and decortication (PD) improve survival in selected patients with malignant pleural mesothelioma (MPM). Yet its value has been questioned because of concern that this extensive surgical procedure may disrupt health-related quality of life (HRQoL).


HRQoL was studied in patients undergoing PD surgery for MPM using EORTC QLQ-C30 instrument at baseline (prior to surgery), 1, 4–5, 7–8, and 10–11 months following surgery. Global health and variables in function and symptom domains were investigated. Sub-groups analyses were performed for ECOG performance status (PS), histological sub-types and pathological tumor volume (pTV). Within-patient comparisons to baseline scores were made using Wilcoxon signed-rank test. Trends over time were evaluated using Cuzick’s nonparametric test.


There were 114 patients with median age of 70 years (range: 50–88) and PS 0: 35 (30.7%), epithelioid histology: 61 (53.5%) and volume <600 ml: 58 (50.9%). Patients with good PS (PS 0), epithelioid histology and small pTV had greater level of functioning and were less symptomatic at baseline. Overall global health worsened at the first postoperative month (p = 0.0005) with subsequent improvement. Non-epithelioid histology and patients with large pTV demonstrated greater improvement in global health, function and symptoms domains following a PD.


At baseline, the overall health-related quality of life, function and symptom domains were adversely affected in non-epithelioid histology and patients with large pTV. However, greatest improvement in global health, symptom and function domains were observed first month after PD and during the follow-up in these sub-groups.


Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Betta PG, Magnani C, Bensi T et al (2012) Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. Arch Pathol Lab Med 136(253):261Google Scholar
  2. 2.
    Elliot W, Kammerstern M, Churg J (1983) Tumors and pseudotumors of the serous membranes. In: Atlas of tumor pathology. Second series, fascicle 20. Armed Forces Institute of Pathology, Washington, DCGoogle Scholar
  3. 3.
    Hillerdal G (1983) Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77:321–343CrossRefPubMedGoogle Scholar
  4. 4.
    Rusch VW, Giroux D (2012) Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg 1(4):438.48PubMedGoogle Scholar
  5. 5.
    Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52Google Scholar
  6. 6.
    Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Rusch VW (2014) Supplementary prognostic variables for pleural mesothelioma a report from the IASLC Staging Committee. J Thorac Oncol 9(6):856.64CrossRefPubMedGoogle Scholar
  7. 7.
    Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472–481CrossRefPubMedGoogle Scholar
  8. 8.
    Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620–626CrossRefPubMedGoogle Scholar
  9. 9.
    Burt BM, Cameron RB, Mollberg NM, Kosinski AS, Schipper PH, Shrager JB, Vigneswaran WT (2014) Malignant pleural mesothelioma and the society of thoracic surgeons database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg 148(1):30.5PubMedGoogle Scholar
  10. 10.
    Mollberg NM, Vigneswaran Y, Kindler HL et al (2012) Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg 94:1086–1092CrossRefPubMedGoogle Scholar
  11. 11.
    Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. on behalf of the EORTC Quality of Life Group. Brussels: EORTC. ISBN: 2-9300 64-22-6Google Scholar
  12. 12.
    Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304.12CrossRefPubMedGoogle Scholar
  13. 13.
    Vigneswaran WT, Kircheva DY, Ananthanarayanan V, et al (2017) Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma. Ann Thorac Surg 103(3):962–966CrossRefPubMedGoogle Scholar
  14. 14.
    Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52Google Scholar
  15. 15.
    Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD (2001) Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78:171–174CrossRefPubMedGoogle Scholar
  16. 16.
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMedGoogle Scholar
  17. 17.
    Rusch V, Baldini EH, Bueno R et al (2013) participants in 2012 International Mesothelioma Interest Group Congress. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, MA. J Thorac Cardiovasc Surg 145:909–910CrossRefPubMedGoogle Scholar
  18. 18.
    Sharkey AJ, Tenconi S, Nakas A, Waller DA (2016) The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg 49(6):1632–1641CrossRefPubMedGoogle Scholar
  19. 19.
    Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT (2016) Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg 49(6):1642–1647CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2017

Authors and Affiliations

  • Wickii T. Vigneswaran
    • 1
    • 5
    Email author
  • Diana Y. Kircheva
    • 1
    • 5
  • Adrian E. Rodrigues
    • 5
  • Sydeaka Watson
    • 2
  • Amy Durkin Celauro
    • 1
  • Berkley Rose
    • 3
  • Hedy L. Kindler
    • 3
  • Aliya N. Husain
    • 4
  1. 1.Section of Cardiac and Thoracic Surgery, Department of SurgeryUniversity of Chicago MedicineChicagoUSA
  2. 2.Department of BiostatisticsUniversity of Chicago MedicineChicagoUSA
  3. 3.Section of Hematology and Oncology, Department of MedicineUniversity of Chicago MedicineChicagoUSA
  4. 4.Department of PathologyUniversity of Chicago MedicineChicagoUSA
  5. 5.Department of Thoracic and Cardiovascular SurgeryLoyola University Medical CenterMaywoodUSA

Personalised recommendations